The high failure rate of drugs in human trials after passing animal tests stems from a fundamental biological reality: a "mouse is not a small human." This "structural mismatch" is especially severe for modern, human-specific therapies like CAR-T and RNA, rendering animal models poor proxies.

While AI excels at screening vast compound libraries for potential drug candidates, it cannot overcome the ultimate bottleneck: the messy, complex, and poorly documented reality of human biology. The need for physical clinical trials remains the fundamental constraint on medical progress.

The push away from animal models is a technical necessity, not just an ethical one. Advanced therapeutics like T-cell engagers and multispecific antibodies depend on human-specific biological pathways. These mechanisms are not accurately reproduced in animal models, rendering them ineffective for testing these new drug classes.

Despite hype around alternative methods, animal models will remain essential in drug development for the foreseeable future. The CEO argues that AI and ML will primarily make these studies more efficient by reducing the number of animals needed and improving data interpretation, not by eliminating the preclinical animal testing stage entirely.

Despite the buzz, a clinical development expert cautions that AI's impact in drug development is limited. The primary bottleneck isn't the algorithms but the lack of sufficient, high-quality human biological data that can be translated into reliable predictions, as animal models often fail to provide it.

Unlike using genetically identical mice, Gordian tests therapies in large, genetically varied animals. This variation mimics human patient diversity, helping identify drugs that are effective across different biological profiles and addressing patient heterogeneity, a primary cause of clinical trial failure.

The NIH will no longer award funding to new grant proposals that rely exclusively on animal models. This policy forces a shift towards New Approach Methodologies (NAMs), such as organoids and organ-on-chips, serving as a major catalyst for innovation and adoption in the preclinical testing space.

The FDA is eliminating mandatory animal testing because it's often misleading—90% of drugs passing animal studies fail in humans. The agency is embracing modern alternatives like computational modeling and organ-on-a-chip technology to get faster, more accurate safety data.

A significant, often overlooked, hurdle in drug development is that therapeutic antibodies bind differently to animal targets than human ones. This discrepancy can force excessively high doses in animal studies, leading to toxicity issues and causing promising drugs to fail before ever reaching human trials.